Clonal Hematopoiesis of Indeterminate Potential and Incident Hypertension: Results From the Women's Health Initiative
- PMID: 40106531
- PMCID: PMC11925488
- DOI: 10.1161/HYPERTENSIONAHA.124.24482
Clonal Hematopoiesis of Indeterminate Potential and Incident Hypertension: Results From the Women's Health Initiative
Keywords: blood pressure; clonal hematopoiesis/genetics; hypertension.
Conflict of interest statement
B. Haring reports speaker honoraria from Pfizer and Bristol-Myers Squibb. M. Böhm is supported by the German Research Foundation and reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor, Servier, and Vifor. P. Natarajan reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech/Roche, and Novartis; personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis; scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio; scientific cofounder of TenSixteen Bio, equity in Preciseli and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. The other authors report no conflicts.
References
-
- Polizio AH, Marino L, Min KD, Yura Y, Rolauer L, Cochran JD, Evans MA, Park E, Doviak H, Miura-Yura E, et al. Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism. Circ Res. 2024;135:933–950. doi: 10.1161/circresaha.124.324492 - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
